Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of $1.25, $0.16 worse than the analyst estimate of $1.41. Revenue for the quarter came in at $69.9 million versus the consensus estimate of $71.27 million.

“Enanta’s research and development programs are progressing well and we have many clinical goals that we expect to achieve this year,” said Jay R. Luly, Ph.D. President and CEO, Enanta Pharmaceuticals. “By mid-year, we expect to announce top-line data from our Phase 2a human challenge study of EDP-938 for RSV, followed by Phase 2a data from our NASH study. We also expect to initiate a Phase 1 study with our new HBV core inhibitor candidate EDP-514 in the second half of 2019.”

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.